Dupixent gets closer to EU approval as the FDA delays its decision on COPD
Sanofi and Regeneron’s blockbuster drug Dupixent (dupilumab) is nearing approval for a new indication, as it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for chronic obstructive pulmonary disease (COPD). …